Skip Navigation



Japanese Journal of Clinical Oncology Advance Access published online on April 3, 2008
Japanese Journal of Clinical Oncology, doi:10.1093/jjco/hyn025
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
38/5/387    most recent
hyn025v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Nakamura, K.
Right arrow Articles by Hiraoka, M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nakamura, K.
Right arrow Articles by Hiraoka, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author (2008). Published by Oxford University Press. All rights reserved

Accelerated Fractionation versus Conventional Fractionation Radiation Therapy for Glottic Cancer of T1-2N0M0 Phase III Study: Japan Clinical Oncology Group Study (JCOG 0701)

Kenichi Nakamura1, Takeshi Kodaira2, Naoto Shikama3, Yoshikazu Kagami4, Satoshi Ishikura1, Taro Shibata1 and Masahiro Hiraoka5

1 Clinical Trials and Practice Support Division, Center for Cancer Control and Information Services, National Cancer Center, Tokyo
2 Department of Radiation Oncology, Aichi Cancer Center Hospital, Nagoya
3 Department of Radiology, Shinshu University School of Medicine, Nagano
4 Radiation Oncology Division, National Cancer Center Hospital, Tokyo
5 Department of Radiation Oncology and Image-applied Therapy, Kyoto University Hospital, Kyoto, Japan

For reprints and all correspondence: Takeshi Kodaira, Department of Radiation Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, 464-8681, Japan. E-mail: 109103{at}aichi-cc.jp

Received December 11, 2007; accepted March 1, 2008

A randomized Phase III study was started in Japan to demonstrate the non-inferiority of survival of accelerated fractionation radiation therapy (2.4 Gy/fr) with conventional fractionation radiation therapy (2 Gy/fr) in patients with T1-2N0M0 glottic cancer. This study began in September 2007, and a total of 360 patients will be accrued from 22 institutions within 4 years. The primary endpoint is 3-year progression-free survival (PFS). The secondary endpoints are overall survival, local progression-free survival, disease-free survival, survival with preserved voice function, complete response rate, proportion of treatment completion and adverse events.

Key Words: laryngeal neoplasms • radiotherapy • dose fractionation • clinical trials • phase III


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.